SER - NYSE
Serina Therapeutics, Inc.
$5.00
+0.0000%Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
At a Glance
Live SnapshotSerina Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.
Serina Therapeutics, Inc. Balance Sheet
SER • NYSE
| Serina Therapeutics, Inc. Balance Sheet | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
CURRENT ASSETS | |||||||||
3.7M | 345K | 532.2K | 314.8K | 527K | 2.4M | 6.7M | 7.4M | 259K | |
0.0 | 0.0 | 0.0 | 996.4K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
3.7M | 7.6M | 532.2K | 1.3M | 527K | 2.4M | 6.7M | 7.4M | 259K | |
0.0 | 57K | 4K | 1.1K | 326K | 363K | 131K | 107K | 308K | |
0.0 | 57K | 4K | 1.1K | 326K | 363K | 131K | 107K | 308K | |
1.9M | 0.0 | 16.3K | 17.9K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
77K | -57K | -4K | 0.0 | 1.4M | 1.3M | 1M | 111K | 121K | |
5.7M | 7.6M | 548.6K | 1.3M | 2.3M | 4.1M | 7.9M | 7.6M | 688K | |
NON-CURRENT ASSETS | |||||||||
1M | 0.0 | 309.5K | 514.2K | 0.0 | 1.1M | 90K | 129K | 195K | |
0.0 | 607K | 738K | 870K | 1.6M | 2.2M | 0.0 | 0.0 | 0.0 | |
0.0 | 607K | 738K | 870K | 1.6M | 2.2M | 0.0 | 0.0 | 0.0 | |
0.0 | 10.6M | 50K | 0.0 | 50K | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | -788K | -870K | 0.0 | 111K | 2.7M | 1.9M | 2.3M | |
1M | 11.2M | 309.5K | 514.2K | 1.6M | 3.4M | 2.8M | 2M | 2.5M | |
6.7M | 12M | 858K | 1.8M | 3.9M | 7.4M | 10.7M | 9.6M | 3.2M | |
LIABILITIES | |||||||||
CURRENT LIABILITIES | |||||||||
744K | 580K | 148.9K | 149.8K | 761K | 420K | 150K | 75K | 261K | |
744K | 580K | 143.3K | 145.5K | 761K | 420K | 150K | 75K | 261K | |
0.0 | 0.0 | 5.5K | 4.3K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
559K | 0.0 | 6.9K | 9.9K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 3.7M | 0.0 | 7.1M | 2.4M | 428K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 128.4K | 211.8K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 153.5K | 0.0 | 275K | 283K | 317K | 180K | 264K | |
1.1M | 1.7M | 0.0 | -7.1M | 1.9M | 2.2M | 2M | 1.1M | 25.1M | |
2.4M | 5.9M | 437.7K | 371.5K | 5.4M | 3.3M | 2.4M | 1.3M | 25.6M | |
NON-CURRENT LIABILITIES | |||||||||
0.0 | 693K | 1.6M | 6.1M | 3.9M | 1.5M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 64K | 0.0 | 0.0 | 0.0 | 0.0 | |
3.6M | 0.0 | 36.5M | 36.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
3.9M | 693K | 38.2M | 36.6M | 4M | 1.5M | 0.0 | 0.0 | 0.0 | |
268K | 462K | 191.7K | 398.2K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
6.2M | 6.6M | 38.6M | 37M | 9.3M | 4.8M | 2.4M | 1.3M | 25.6M | |
SHAREHOLDERS' EQUITY | |||||||||
6.7M | 36.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1K | 0.0 | 4K | 4K | 4K | 4K | 4K | 3K | 3K | |
45M | 136.5M | 99M | 93.9M | 91.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
-44.3M | -131M | -116.2M | -105.7M | -97.1M | -86.2M | -74.1M | -66.6M | -60M | |
0.0 | 0.0 | 0.0 | 0.0 | 143K | 69K | -2K | 68K | 58K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 88.4M | 81.5M | 73.8M | 36.5M | |
641K | 5.5M | -17.2M | -11.8M | -5.1M | 2.2M | 7.4M | 7.3M | -23.4M | |
508K | 5.4M | -37.8M | -35.1M | -5.4M | 2.6M | 8.2M | 8.3M | -22.4M | |
-133K | -111K | -103K | -43K | -280K | 399K | 784K | 1M | 1M | |
SUMMARY | |||||||||
6.7M | 12M | 858K | 1.8M | 3.9M | 7.4M | 10.7M | 9.6M | 3.2M | |
0.0 | 10.6M | 50K | 996.4K | 50K | 0.0 | 0.0 | 0.0 | 0.0 | |
268K | 4.4M | 1.8M | 398.2K | 6.3M | 2M | 0.0 | 0.0 | 0.0 | |
-3.4M | 4M | 1.3M | 83.3K | 5.8M | -396K | -6.7M | -7.4M | -259K | |
10,250,600 | 10,250,600 | 10,250,600 | 10,250,600 | 10,250,600 | 10,250,600 | 10,250,600 | 10,250,600 | 10,250,600 |
SEC Filings
SER - Filing history and reports
No SEC filings available for SER
Related Guides
Continue your SER research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.